Mercury Laboratories Ltd

Mercury Labs has experienced mixed financial performance, with net sales and operating income peaking at 75.56 Cr in Mar'24 before declining to 75.10 Cr in Mar'25, while profitability metrics such as profit after tax and earnings per share significantly decreased. Despite an increase in total assets, cash flow from operations fell sharply, indicating financial challenges.

Mercury Laboratories reported a net profit of ₹1.64 crores for Q2 FY26, a 228% increase year-on-year, but revenue growth remains modest at 4.51%. Despite strong profit figures, concerns about declining operating margins and reliance on non-recurring income suggest caution regarding future performance.

As of November 12, 2025, Mercury Labs is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, which are favorable compared to peers like Sun Pharma and Divi's Lab, despite recent underperformance relative to the Sensex.

Mercury Labs has experienced mixed financial performance, with net sales and operating income peaking at 75.56 Cr in Mar'24 before declining to 75.10 Cr in Mar'25, while profitability decreased significantly, resulting in a profit after tax drop from 5.65 Cr to 3.14 Cr in the same period. Despite challenges in profitability, total assets increased from 67.96 Cr to 74.24 Cr.

Mercury Labs has experienced mixed financial performance, with net sales peaking at 75.56 Cr in Mar'24 but declining to 75.10 Cr in Mar'25, alongside a drop in profit after tax from 5.65 Cr to 3.14 Cr. Despite an increase in total assets, profitability and cash flow have decreased, indicating operational challenges.

Mercury Labs' historical performance shows mixed results, with net sales slightly decreasing to 75.10 Cr in Mar'25, while total assets increased to 74.24 Cr. However, profitability declined, with profit after tax dropping to 3.14 Cr from 5.65 Cr in the previous year.

Mercury Labs has experienced mixed historical performance, with net sales and operating income peaking at 75.56 Cr in Mar'24 before declining to 75.10 Cr in Mar'25, while profitability metrics such as profit after tax fell from 5.65 Cr to 3.14 Cr during the same period. Despite an increase in total assets, cash flow from operating activities significantly decreased, resulting in a net cash outflow of 6.00 Cr in Mar'25.

As of 03-Nov, Mercury Laboratories Ltd's stock price is Rs 849.40, down 1.71%, and has underperformed its sector by 3.01%. The stock is in a bearish trend, trading below key moving averages, with a year-to-date decline of 5.20% compared to the Sensex's gain of 7.47%.

As of 30-Oct, Mercury Laboratories Ltd is currently priced at 904.00, reflecting a 3.31% increase and strong short-term performance, but with a significant drop in investor participation. Despite recent gains, its year-to-date performance remains modest compared to the Sensex.

Mercury Labs has experienced mixed financial performance, with net sales and operating income peaking at 75.56 Cr in Mar'24 before declining to 75.10 Cr in Mar'25. Despite growth in total assets, profitability metrics such as profit after tax fell from 5.65 Cr to 3.14 Cr during the same period.

Mercury Labs has experienced mixed financial performance, with net sales slightly decreasing to 75.10 Cr in March 2025, while operating profit and profit after tax declined significantly. Despite growth in total assets, rising costs have pressured profit margins.

As of 20-Oct, Mercury Laboratories Ltd's stock price is 840.00, down 4.11%, underperforming its sector and the Sensex. The stock has shown weak trading patterns, with a significant decline in delivery volume and a year-to-date drop of 6.25%, contrasting with the Sensex's rise of 7.97%.